Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells (Q69500063)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 January 1989

Language	Label	Description	Also known as
English	Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells	scientific article published on 01 January 1989

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

Elisabeth Paietta

2

object named as

E Paietta

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

Peter H. Wiernik

4

object named as

P H Wiernik

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

Janice P Dutcher

3

object named as

J Dutcher

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

publication date

1 January 1989

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

115

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

170-174

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

NIH conference. Immunomodulators in clinical medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The standardization of NK cell assays for use in studies of biological response modifiers

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo and in vitro activation of NK cytotoxicity with IL-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/2654134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00397919

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2654134%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q69500063&oldid=2222597547"